London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...
Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...
Amsterdam (ots/PRNewswire) - Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment of Saulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience and a unique blend of ...
Amsterdam (ots/PRNewswire) - Today, Norgine Europe B.V. ("Norgine", the "Company"), a leading European specialty pharmaceutical company, announced that the Private Equity business within Goldman Sachs Asset Management will acquire a majority stake in the Company from the Stein Family, who will continue to own a significant stake in the Company. The transaction is a key milestone in Norgine's history, following over 110 ...
Amsterdam (ots/PRNewswire) - Norgine B.V. (Norgine), a leading European specialist pharmaceutical company, today announces that Christopher Bath has been appointed Chief Executive Officer (CEO) effective 1st January 2022. Chris will be responsible for a business with a portfolio of market leading medicinal products ...
Amsterdam (ots/PRNewswire) - NORGINE B.V. (Norgine), a leading European specialist pharmaceutical company, celebrates its 30th anniversary of continuous innovation in bowel preparations at the United European Gastroenterology (UEG) Week Virtual. Bowel preparations are used in colonoscopy to prevent and diagnose ...
Amsterdam (ots/PRNewswire) - NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and Beijing Podconley Pharmaceutical Technology & Development Co., Ltd. (Beijing Podconley), today announced an exclusive distribution agreement by which Beijing Podconley will commercialise Norgine's product ...
Amsterdam, The Netherlands (ots/PRNewswire) - Norgine B.V. ("Norgine"), today announced the establishment of a wholly-owned subsidiary, Norgine Healthcare B.V. ("Norgine Healthcare"), which will be dedicated to consumer healthcare. To view the Multimedia News Release, please click: ...
Amsterdam (ots/PRNewswire) - - Norgine will now seek to extend ANGUSTA®'s licence to a number of European countries - ANGUSTA®'s licence extension for these countries will be subject to national approvals Norgine B.V. (Norgine) today announced the successful completion of the Repeat Use Procedure (RUP) for ...
Amsterdam (ots/PRNewswire) - Norgine B.V. (Norgine) today announced that Christopher Bath has been appointed Chief Operating Officer (COO) effective 1st July 2020. Chris, who has been Norgine's Chief Financial Officer since 2014, will report to Peter Stein, Chairman and Chief Executive Officer (CEO) of Norgine. He will be responsible for all global operations. Chris ...
Amsterdam (ots/PRNewswire) - Norgine B.V. ("Norgine") announces the acquisition of Azanta A/S, a specialty biopharmaceutical company operating within women's healthcare, addiction medicine and oncology. Azanta becomes a wholly-owned subsidiary of Norgine. To view the Multimedia News Release, please click: ...
Amsterdam (ots/PRNewswire) - - Ferric maltol (FM) was associated with substantially lower use of healthcare resources than IV ferric carboxymaltose (FCM) - IV FCMwas linked to greater productivity loss and disruption to patients' work and family life due to the need for clinic-based IV administration - 50% of ...
Amsterdam (ots/PRNewswire) - - Norgine to receive upfront payments, undisclosed milestone payments along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries Norgine B.V. (Norgine), a leading European specialist pharmaceutical company, today ...
Amsterdam (ots/PRNewswire) - Norgine B.V. highlighted new data from a study supported by its partner company Shield Therapeutics, presented today at the United European Gastroenterology (UEG) Week in Barcelona showing that ferric maltol, a novel oral iron replacement therapy, was found to be non-inferior to ...
Amsterdam (ots/PRNewswire) - SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisai Inc., upholding SpePharm's licensed rights for SALAGEN® (pilocarpine hydrochloride) ...
Amsterdam (ots/PRNewswire) - - Rifaximin significantly reduced the incidence of all-cause hospital admissions in HE patients with advanced cirrhosis on the waiting list for liver transplantation - Rifaximin contributed to improved outcomes in HE patients on the waiting list helping patients stay out of hospital for ...
- Rifaximin-a in combination with lactulose, the standard of care (SOC) treatment resulted in significant reductions ...
Amsterdam (ots/PRNewswire) - - FERACCRU® (Ferric Maltol) met primary endpoint against Ferinject® (IV Ferric Carboxymaltose (FCM)) and shows clear benefits to Iron Deficiency Anaemia (IDA) patients with inactive Inflammatory Bowel Disease (IBD)4 - FERACCRU® delivered a haemoglobin (Hb) response rate at 12 weeks ...
Amsterdam (ots/PRNewswire) - Norgine B.V. today announced that its UK affiliate has received funding for ENDOCUFF VISION® through the NHS Innovation Technology Payment 2018/19 (ITP) scheme. The NHS ITP Programme aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake of innovative products or technologies and is a ...
Amsterdam (ots/PRNewswire) - Arc Medical Design Limited, a subsidiary of Norgine B.V., today announced that the High Court of Justice England and Wales, Patents Court ruled that ENDOCUFF® and ENDOCUFF VISION® UK national and UK(EP) patents (as amended) are valid and infringed by Cantel's AmplifEYE® endoscopic ...
Toronto and Amsterdam (ots/PRNewswire) - - Norgine to acquire all outstanding shares of Merus for $1.65 per share in cash Merus Labs International Inc. ("Merus" or the "Company") TSX: MSL, NASDAQ: MSLI and Norgine B.V. ("Norgine") announced today that they have entered into a definitive agreement (the "Arrangement Agreement") under which Norgine will acquire all of the issued and outstanding common shares of Merus for ...
London (ots/PRNewswire) - Norgine B.V. today announced that it has completed the divestment of its MENA operations and product rights for MOVICOL®, MOVIPREP®, KLEAN-PREP® and NORMACOL® in MENA to Acino. (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) Peter Stein, CEO at Norgine said: "The divestment ...
London (ots/PRNewswire) - Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy (HE) where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition ...
Amsterdam (ots/PRNewswire) - Norgine BV (Amsterdam) and SpePharm Holding BV (Amsterdam) announced today that they have concluded a broad collaboration agreement under which the two companies have invested in a 50:50 joint venture, SpePharm AG, which has acquired the entire product portfolio of SpePharm Holding, including Savene(R), MuGard(R), Xerotin(R), PROther(R) and the Dantrium(R) brands. The new joint venture will ...